Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen, a U.S. pharmaceutical company with an original drug, is filing a patent lawsuit that has blocked the osteoporosis treatment drugs Prolia and Xgeva biosimilars (biopharmaceutical generic ...

Taken alongside Prolia/Xgeva, the brands account for well over 40% of Amgen's current revenues. Other companies working on biosimilar versions of denosumab include Samsung Bioepis, Celltrion, and ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.

with 1 in 10 of the town folk working for Amgen." However, the company seems to have weathered those storms for the time being, and the recent approval of Prolia, its new monoclonal antibody for ...